Effect of vitamin D supplementation on N-glycan branching and cellular immunophenotypes in MS.

Priscilla Bäcker-Koduah, Carmen Infante-Duarte, Federico Ivaldi, Antonio Uccelli, Judith Bellmann-Strobl, Klaus-Dieter Wernecke, Michael Sy, Michael Demetriou, Jan Dörr, Friedemann Paul, Alexander Ulrich Brandt

Journal: Annals of clinical and translational neurology 2021;7(9):1628-1641

PMID: 32830462

Abstract

[{"label":"OBJECTIVE","text":"To investigate the effect of cholecalciferol (vitamin D3) supplementation on peripheral immune cell frequency and N-glycan branching in patients with relapsing-remitting multiple sclerosis (RRMS)."},{"label":"METHODS","text":"Exploratory analysis of high-dose (20\u00a0400\u00a0IU) and low-dose (400\u00a0IU) vitamin D3 supplementation taken every other day of an 18-month randomized controlled clinical trial including 38 RRMS patients on stable immunomodulatory therapy (NCT01440062). We investigated cholecalciferol treatment effects on N-glycan branching using L-PHA stain (phaseolus vulgaris leukoagglutinin) at 6\u00a0months and frequencies of T-, B-, and NK-cell subpopulations at 12\u00a0months with flow cytometry."},{"label":"RESULTS","text":"High-dose supplementation did not change CD3+\u00a0T cell subsets, CD19+ B cells subsets, and NK cells frequencies, except for CD8+\u00a0T regulatory cells, which were reduced in the low-dose arm compared to the high-dose arm at 12\u00a0months. High-dose supplementation decreased N-glycan branching on T and NK cells, measured as L-PHA mean fluorescence intensity (MFI). A reduction of N-glycan branching in B cells was not significant. In contrast, low-dose supplementation did not affect N-glycan branching. Changes in N-glycan branching did not correlate with cell frequencies."},{"label":"INTERPRETATION","text":"Immunomodulatory effect of vitamin D may involve regulation of N-glycan branching in vivo. Vitamin D3 supplementation did at large not affect the frequencies of peripheral immune cells."},{"copyright":"\u00a9 2020 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association."}]
Address: Charité - Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin, Humboldt - Universität zu Berlin, and Berlin Institute of Health, NeuroCure Cluster of Excellence, Berlin, Germany.; Experimental and Clinical Research Center, Max Delbrueck Center for Molecular Medicine and Charité - Universitätsmedizin Berlin, Berlin, Germany.; Charité - Universitätsmedizin Berlin, Institute for Medical Immunology, Berlin, Germany.; Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, CEBR University of Genoa, Genoa, Italy.; Ospedale Policlinico San Martino-IRCCS, Genoa, Italy.; Berlin Institute of Health, NeuroCure Cluster of Excellence, Department of Neurology, Charité - Universitätsmedizin Berlin, Berlin, Germany.; Institute of Biometry and Clinical Epidemiology, Charité -Universitatsmedizin Berlin and CRO SOSTANA GmbH, Berlin, Germany.; Department of Neurology, University of California, Irvine, CA, USA.; Multiple Sclerosis Center Hennigsdorf, Oberhavel Clinics, Berlin, Germany.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.